Defense Health Agency Contracting Activity - DHACA

Description

Applications to the Fiscal Year 2015 (FY15) Reconstructive Transplant Research (RTR) program) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA RDA Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. This Program Announcement/Funding Opportunity and subsequent awards will be managed and executed by the Congressionally Directed Medical Research Programs (CDMRP) with strategic oversight from Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP). To meet the intent of the FY15 RTR award mechanisms, applicants must address one or more of the Focus Areas listed below.• Immune system regulation• Improved access to reconstructive transplantation• Reconstructive transplantation rehabilitation• Graft surveillance – Clinical monitoring• Psychosocial issues associated with VCA.The RTR Clinical Trial Award (RTR CTA) mechanism is being offered for the first time in FY15. A synopsis of all FY15 RTR Program Announcements/Funding Opportunities is available at http://cdmrp.army.mil/funding/pdf/15rtrpreftable.pdf.The intent of the FY15 RTR CTA mechanism is to support clinical trials with the potential to have a major impact on improving the function, wellness, and overall quality of life for injured Service members and Veterans, their caregivers and family members, and the American public. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. PIs seeking funding for a preclinical research project should consider one of the other FY15 RTR award mechanisms/funding opportunities being offered.

Who can apply

• Unrestricted

Contact

301-682-5507; help@cdmrp.org.
help@cdmrp.org.